CTOs on the Move

VEXIOM HOLDINGS CORPORATION

www.vexiom.com

 
VEXIOM HOLDINGS CORPORATION is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.vexiom.com
  • 3232 Cobb Pkwy SE
    Atlanta, GA USA 30339
  • Phone: 404.496.5304

Executives

Name Title Contact Details

Similar Companies

Biosearch Technologies

Biosearch Technologies is a Novato, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company`s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

Cyagen Biosciences

Cyagen Biosciences is a 400-employee company headquartered in Santa Clara, California, with additional locations in Germany, Japan and China. Cyagen is the world`s largest provider of custom-engineered mouse and rat models. Cyagen`s services have become well known for their top quality, full guarantee, and competitive prices.

Girindus America

Girindus America is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.